IPR In Litigation Strategies For Immunotherapy Patents
1. Introduction: Immunotherapy Patents and IPR
Immunotherapy refers to treatments that use the body’s immune system to fight diseases, particularly cancers and autoimmune disorders. This field includes:
Monoclonal antibodies (mAbs)
CAR-T cell therapies
Immune checkpoint inhibitors (PD-1, CTLA-4 inhibitors)
Cytokine therapies and vaccines
Intellectual property in immunotherapy often covers:
Composition of matter patents – e.g., specific antibodies or engineered cells.
Method-of-treatment patents – using a compound for a disease indication.
Manufacturing process patents – methods of producing cells, antibodies, or vaccines.
Diagnostic or biomarker patents – methods to select patients for therapy.
Litigation arises frequently because immunotherapy patents are high-value and often involve overlapping claims across multiple companies.
2. Litigation Strategies in Immunotherapy Patents
Effective litigation strategies usually include:
Establishing Patent Validity
Countering challenges of obviousness, novelty, or enablement.
Infringement Analysis
Literal infringement versus doctrine of equivalents.
Claim Scope Interpretation
Narrow vs. broad claims (composition, methods, or processes).
Cross-Licensing and Portfolio Negotiation
High-value patents often result in settlements or cross-licensing agreements.
Regulatory and Market Leverage
Coordinating litigation with FDA/EMA exclusivity and market approvals.
Defensive Strategies
Preemptive patent filing, invalidity countersuits, and licensing challenges.
3. Key Case Laws in Immunotherapy Patent Litigation
CASE 1: Amgen Inc. v. Sanofi & Regeneron (PCSK9 antibody patents)
Background:
Amgen sued Sanofi/Regeneron over patents covering PCSK9 antibodies for lowering cholesterol.
Legal Issues:
Patent infringement on composition-of-matter claims.
Claim interpretation of functional antibody binding sites.
Outcome:
Courts upheld several Amgen patents.
Sanofi/Regeneron modified their antibody and entered settlement agreements for remaining claims.
Significance:
Demonstrates the importance of functional claim scope.
Cross-licensing and settlements are common in overlapping biotech portfolios.
CASE 2: Novartis v. Bristol-Myers Squibb (CAR-T cell therapy)
Background:
Novartis held patents on CAR-T constructs; BMS filed competing CAR-T therapy patents.
Legal Issues:
Overlapping method-of-treatment and composition claims.
Patent interference and derivation proceedings in the U.S. Patent Office.
Outcome:
Interference resolved in favor of Novartis for certain CAR-T constructs.
Licensing agreements executed for overlapping areas.
Significance:
Highlights strategic use of interference proceedings to establish priority in high-value immunotherapy patents.
CASE 3: Genentech v. Immunex (Anti-PD1/PDL1 checkpoint inhibitors)
Background:
Genentech sued Immunex for infringing patents covering immune checkpoint inhibitors.
Legal Issues:
Method-of-treatment patents for inhibiting PD-1/PD-L1 pathways in cancer therapy.
Determining infringement on combination therapies.
Outcome:
Court upheld Genentech’s patent validity.
Injunctions threatened commercial products, resulting in licensing negotiations.
Significance:
Method-of-treatment patents can provide strong leverage in negotiating royalties or settlements.
CASE 4: Seattle Genetics v. ImmunoGen (Antibody-Drug Conjugates, ADCs)
Background:
Seattle Genetics alleged ImmunoGen infringed patents covering ADC linkers and conjugation methods.
Legal Issues:
Composition-of-matter and process patent infringement.
Doctrine of equivalents applied to linker chemistry.
Outcome:
Court found partial infringement; damages awarded for certain products.
Licensing deals followed for continued market access.
Significance:
ADC patent litigation demonstrates combined enforcement of product and process patents in immunotherapy.
CASE 5: Kite Pharma v. Juno Therapeutics (CAR-T & TCR therapy patents)
Background:
Kite Pharma filed suit against Juno for infringing patents covering CAR-T cell modifications.
Legal Issues:
Infringement of composition and process claims.
Claim construction disputes over specific T-cell receptor modifications.
Outcome:
Court enforced certain composition claims and awarded damages.
Settlement and licensing followed for overlapping CAR-T technologies.
Significance:
Reinforces strategy of asserting overlapping patents to secure licensing leverage in competitive immunotherapy markets.
CASE 6: Amgen v. F. Hoffmann-La Roche (Monoclonal antibody oncology patents)
Background:
Amgen sued Roche for infringement of monoclonal antibody patents targeting oncology biomarkers.
Legal Issues:
Validity of claims challenged on obviousness and written description grounds.
Patent scope included both composition and method claims.
Outcome:
Court upheld key patents, leading to licensing negotiations.
Some claims invalidated, highlighting strategic claim drafting importance.
Significance:
Demonstrates dual approach: defend validity while enforcing commercial leverage.
4. Key Litigation Strategies for Immunotherapy Patents
Comprehensive Portfolio Analysis
Map all patents covering composition, methods, manufacturing, and biomarkers.
Early Claim Construction
Interpret scope of composition and method claims accurately before filing suits.
Pre-Litigation Negotiation and Licensing
High-value immunotherapy patents often resolve via cross-licensing.
Regulatory Integration
Combine FDA/EMA exclusivity and IP enforcement for stronger market leverage.
Defensive Patent Filing
Block competitors and prevent design-around strategies.
Use of Expert Testimony
Scientific complexity requires expert analysis for infringement and validity in court.
5. Challenges in Immunotherapy Patent Litigation
Overlapping claims between multiple biotech companies
Rapid innovation leading to obsolescence of patents
High cost of litigation and expert witnesses
Complex claim construction for biological and biochemical entities
International enforcement issues when therapies are marketed globally
6. Conclusion
Immunotherapy patent litigation is a high-stakes, strategically complex field. Key lessons from cases:
Amgen v. Sanofi/Regeneron & Amgen v. Roche: Functional and composition claims are powerful leverage.
Novartis v. BMS & Kite Pharma v. Juno: Priority and interference proceedings can protect market share.
Genentech v. Immunex & Seattle Genetics v. ImmunoGen: Method-of-treatment and process patents are enforceable and highly valuable.
Effective litigation strategies combine:
Careful portfolio mapping
Early claim construction
Strategic settlements or licensing
Regulatory leverage
This ensures protection of valuable immunotherapy innovations while maintaining market advantage.
RELATED Blog
comments